Korean J Hematol 2005; 40(3):
Published online September 30, 2005
https://doi.org/10.5045/kjh.2005.40.3.142
© The Korean Society of Hematology
김성현, 이동미, 서봉근, 권혁찬, 김재석, 한진영, 김효진
동아대학교 의과대학 내과학교실, 진단검사의학교실
Background:
There has been changed in estimation of the stem cell content of the graft for several decades. However, there is not always correlating the transplanted cell dose with hematologic recovery, and there are few reports in human leukocyte antigen (HLA)-matched sibling allogeneic bone marrow transplantation (AlloBMT) in Korea. The purpose of this study is to report the influence of number of transplanted cell dose on hematologic recovery and the clinical outcomes in HLA-matched sibling AlloBMT.
Methods: Between June 1999 and March 2004, 31 AlloBMT from HLA-matched sibling donor was done in patients with hematologic malignancy. All patients were conditioned with busulfan and cyclophosphamide. Short course methotrexate and cyclosporine regimen was used for prophylaxis of graft-versus-host disease. We analyzed hematologic recovery time and clinical outcomes according to transplanted cell dose.
Results:
There were 16 male and 15 female patients, with a median age of 34 years (range, 16∼48). Underlying diseases were 17 acute myeloid leukemia, 4 acute lymphoblastic leukemia, 3 myelodysplastic syndrome (high-risk), and 7 chronic myelogenous leukemia. The median number of total nucleated cell (TNC), mononuclear cell (MNC) and CD34+ cell infused was 3.95×108/kg (range, 1.67∼7.30×108/kg), 0.65×108kg (range, 0.11∼2.50×108kg), and 2.32×106kg (range, 0.35∼7.45×106kg), respectively. The median days of neutrophil and platelet engraftment (ANC>500/ՌL and platelet>20,000/L without transfusion) were 15 (range, 10∼19), 16 (range, 7∼37), respectively. Relationship between the rate of neutrophil engraftment and the number of infused TNC was only statistically significant (P=0.038, R20.328). This study showed survival benefit with the increment of CD34+ cell dose without significance statistically (P=0.082).
Conclusion: Although the dose of the number of transplanted MNC and CD34+ cells had no influence on granulocyte or platelet recovery, the number of TNC had only a beneficial effect on neutrophil recovery. The transplanted dose of CD34+ cells, rather than those of TNC and MNC may be related with better survival.
Keywords HLA-matched sibling AlloBMT, Cell dose, Hematologic recovery, Clinical outcome
Korean J Hematol 2005; 40(3): 142-148
Published online September 30, 2005 https://doi.org/10.5045/kjh.2005.40.3.142
Copyright © The Korean Society of Hematology.
김성현, 이동미, 서봉근, 권혁찬, 김재석, 한진영, 김효진
동아대학교 의과대학 내과학교실, 진단검사의학교실
Sung Hyun Kim, Dong Mee Lee, Bong Gun Seo, Hyuk Chan Kwon, Jae Seok Kim, Jin Yeong Han, Hyo Jin Kim
Departments of, Internal Medicine, Laboratory Medicine, Dong, A University College of Medicine, Busan, Korea
Background:
There has been changed in estimation of the stem cell content of the graft for several decades. However, there is not always correlating the transplanted cell dose with hematologic recovery, and there are few reports in human leukocyte antigen (HLA)-matched sibling allogeneic bone marrow transplantation (AlloBMT) in Korea. The purpose of this study is to report the influence of number of transplanted cell dose on hematologic recovery and the clinical outcomes in HLA-matched sibling AlloBMT.
Methods: Between June 1999 and March 2004, 31 AlloBMT from HLA-matched sibling donor was done in patients with hematologic malignancy. All patients were conditioned with busulfan and cyclophosphamide. Short course methotrexate and cyclosporine regimen was used for prophylaxis of graft-versus-host disease. We analyzed hematologic recovery time and clinical outcomes according to transplanted cell dose.
Results:
There were 16 male and 15 female patients, with a median age of 34 years (range, 16∼48). Underlying diseases were 17 acute myeloid leukemia, 4 acute lymphoblastic leukemia, 3 myelodysplastic syndrome (high-risk), and 7 chronic myelogenous leukemia. The median number of total nucleated cell (TNC), mononuclear cell (MNC) and CD34+ cell infused was 3.95×108/kg (range, 1.67∼7.30×108/kg), 0.65×108kg (range, 0.11∼2.50×108kg), and 2.32×106kg (range, 0.35∼7.45×106kg), respectively. The median days of neutrophil and platelet engraftment (ANC>500/ՌL and platelet>20,000/L without transfusion) were 15 (range, 10∼19), 16 (range, 7∼37), respectively. Relationship between the rate of neutrophil engraftment and the number of infused TNC was only statistically significant (P=0.038, R20.328). This study showed survival benefit with the increment of CD34+ cell dose without significance statistically (P=0.082).
Conclusion: Although the dose of the number of transplanted MNC and CD34+ cells had no influence on granulocyte or platelet recovery, the number of TNC had only a beneficial effect on neutrophil recovery. The transplanted dose of CD34+ cells, rather than those of TNC and MNC may be related with better survival.
Keywords: HLA-matched sibling AlloBMT, Cell dose, Hematologic recovery, Clinical outcome
Seong Jun Choi, Je Hwan Lee, Cheol won Suh, Na Mi Youm, Young Ran Chae, Sin Kim, Yeong Joo Min, Jin Hee Park, Dai Young Zang, Jong Soo Choi, Sung Bae Kim, Sang We Kim, Kyoo Hyung Lee, Jung Shin Lee, Woo Kun Kim, Sang Hee Kim
Korean J Hematol 1996; 31(2): 235-245